|
|
Volumn 171, Issue 4, 1999, Pages 175-176
|
|
COX-2 inhibitors: The next generation of non-steroidal anti-inflammatory drugs
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2,3,6 TRICHLOROPHENYLACETIC ACID;
ACETYLSALICYLIC ACID;
ACLIN;
ACT 3;
CELECOXIB;
CYCLOOXYGENASE 1 INHIBITOR;
CYCLOOXYGENASE 2 INHIBITOR;
DICLOFENAC;
ENZYME INHIBITOR;
HISTAMINE H2 RECEPTOR ANTAGONIST;
IBUPROFEN;
INDOMETACIN;
KETOPROFEN;
MEFENAMIC ACID;
MEFIC;
MELOXICAM;
MISOPROSTOL;
MOBILIS;
NAPROGESIC;
NAPROXEN;
NONSTEROID ANTIINFLAMMATORY AGENT;
PIROXICAM;
PROTON PUMP INHIBITOR;
ROFECOXIB;
SULINDAC;
UNCLASSIFIED DRUG;
AGED;
ALZHEIMER DISEASE;
ARTHRITIS;
AUSTRALIA;
CARDIOTOXICITY;
CLINICAL TRIAL;
COLORECTAL CANCER;
COST EFFECTIVENESS ANALYSIS;
DRUG TOLERABILITY;
EDEMA;
EDITORIAL;
ENZYME INHIBITION;
ERADICATION THERAPY;
GASTROINTESTINAL DISEASE;
HEALTH EDUCATION;
HELICOBACTER PYLORI;
HIGH RISK PATIENT;
HOSPITAL ADMISSION;
HUMAN;
MUSCULOSKELETAL DISEASE;
NEPHROTOXICITY;
PATIENT SELECTION;
PEPTIC ULCER;
PRESCRIPTION;
RHEUMATIC DISEASE;
|
|
EID: 0033575684
PISSN: 0025729X
EISSN: None
Source Type: Journal
DOI: 10.5694/j.1326-5377.1999.tb123592.x Document Type: Editorial |
|
Times cited : (4)
|
|
References (20)
|
